Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report

ola Kala shared this article with you from Inoreader Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report Μέσω SAGE Publications: Journal of Oncology Pharmacy Practice: Table of Contents Journal of Oncology Pharmacy Practice, Ahead of Print. IntroductionAlthough, immune check-point inhibitors changed the course of many cancers, the outcomes in sarcomas were rather disappointing with less than 10% response rates. Ewing sarcoma is a poorly differentiated and aggressive tumor mostly seen in the children and adolescents. It's a distinct type of sarcoma with prominent chemosensitivity in the early stages. However, the relapsing disease has a poor prognosis with limited treatment options.Case reportHerein, we represent a case of relapsed Ewing sarcoma treated with multiple lines of chemotherapy.Management & outcome: The patient had a very good response to salvage treatment with a combination of paclitaxel and nivolumab which lasted for twelve months after the cessation of treatment.DiscussionWe think that chemotherapy plus immunotherapy can be an option for Ewing sarcoma patients treated with multiple lines of chemotherapy. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.